Intra-Cellular Therapies, Inc. provides sales guidance for the fiscal year 2023. Full year 2023 CAPLYTA net product sales guidance increased to $460 to $470 million from the previous range of $445 to $465 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
66.31 USD | -0.02% | -6.63% | -7.16% |
07/05 | Sector Update: Health Care Stocks Steady Pre-Bell Tuesday | MT |
07/05 | Transcript : Intra-Cellular Therapies, Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.16% | 7B | |
-2.47% | 89.37B | |
+2.76% | 40.65B | |
-13.65% | 32.81B | |
+52.41% | 25B | |
-17.33% | 15.29B | |
-42.45% | 11.61B | |
-10.48% | 11.49B | |
+6.14% | 8.98B | |
-7.72% | 8.23B |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- Intra-Cellular Therapies, Inc. Provides Sales Guidance for the Fiscal Year 2023